The Latest Cardiac and Vascular News
U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, […]
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) More than 100 sites activated in 20 countries with the pace of enrollment increasing Sufficiently funded into second half of 2025 WALTHAM, […]
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the first quarter ended March 31, 2023 and provided key business updates. “We are excited with the progress […]
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-March – – […]
LONDON, May 16, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million. Cost reduction programs implemented across the global organization resulting in declining operating […]
Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV Dose of 0.5 µg/kg for Continuing the […]
SINGAPORE, MAY 15, 2023 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc. Dr. Turco will lead the commercial strategy for the Vascular Interventions and Structural Heart Franchises […]
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention […]
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of […]
GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update. “We had strong growth at Hyperfine in the […]
